Human diagnostics company RSP Systems AS has been awarded a €2.4 million ($2.7 million) grant as part of the European Union’s Horizon 2020 framework for research and innovation. The funds will be used to launch the non-invasive GlucoBeam glucose monitor. The technology is based on RSP's proprietary technology, Critical Depth Raman Spectroscopy. GlucoBeam was developed using Raman spectroscopy for glucose measurement in living tissue. The technique is commonly used in chemistry to provide a fingerprint by which molecules can be identified. “This vital grant will help to overcome the biggest issue in glucose monitoring: compliance,” said Dr. Anders Weber, CEO of RSP Systems. “For patients to finally be able to measure their glucose levels using the non-invasive GlucoBeam will be a real breath of fresh air. With the completion of a commercial product aided by Horizon 2020, we can now identify the best path to the best partners to make GlucoBeam broadly available to patients in the European and later global markets.” RSP Systems is a biotechnology company focused on using Raman spectroscopy for human diagnostics.